Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA.

Technology in cancer research & treatment - 1 Jan 2026

Zeng Hanqing, Song Li-Ying, Guo Ren, Ding Dan, Zeng Xiaohui, Liu Qiao

Abstract excerpt

ObjectiveInavolisib, a novel highly selective PI3Kα inhibitor, is approved for treating PIK3CA-mutated, hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (PIK3CA-mutated, HR+/HER2- ABC). Given its significant efficacy, as confirmed by the updated INAVO120 III trial, but also its high price, a comprehensive evaluation of its value is warranted. The purpose of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Imidazoles

Share to Oxazoles

Share to Pyridines

Share to Quality-Adjusted Life Years

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 41989051
DOI: 10.1177/15330338261444965
PMCID: PMC13091980

Genes

PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA.PMID 41989051Read ↗

Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer.Semantic proximity Read ↗

Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?Semantic proximity Read ↗

Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.Semantic proximity Read ↗

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read ↗

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.Semantic proximity Read ↗

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read ↗

Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer.Semantic proximity Read ↗

Cost-Effectiveness Analysis of talazoparib Maintenance Treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the USSemantic proximity Read ↗

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.Semantic proximity Read ↗

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Semantic proximity Read ↗

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.Semantic proximity Read ↗

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.